To identify proteins related to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis by leveraging large-scale genetic and proteomic data.
23 associations corresponded to genetic loci not previously reported in GWAS, suggesting novel insights.
APOE abundance linked to subcortical volumes and white matter hyper-intensities, reinforcing its role in neurodegeneration.
New proteins associated with neurodegenerative diseases include complement proteins, microglia, lysosomes, and interleukin-6 pathway, highlighting new therapeutic targets.
Interpretation:
The findings suggest that the plasma proteome plays a significant role in the pathogenesis of neurodegenerative diseases, highlighting new potential biomarkers and therapeutic targets.
Limitations:
The study is limited to populations of European ancestry, which may affect generalizability.
Potential confounding factors not fully accounted for despite co-localization analysis, warranting caution in interpretation.
Conclusion:
This study demonstrates the utility of combining genomic and proteomic data to uncover new insights into neurodegenerative diseases, paving the way for future research and therapeutic developments.
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
